Product currently under development is an immune-modulating oncolytic virus “mOTS-400” platform and autologous cell therapy “UTTA CAR-T cell”.
They are focused primarily on developing cutting-edge biological products targeting solid tumors.
| Contact Details | #1905, Park View Tower, 248, Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do +82-31. 719. 9179 |
|---|
Find out more companies
Related products
-
-
-
-
-
VentureAprogen
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid